Executive Summary
This digest covers 34 SEC filings from November 4, 2026, focused on board room changes, officer transitions, and governance actions. A significant wave of C-suite and board appointments is underway, with notable CEO transitions at HP Inc.
(Emma Walmsley), MNTN (Tony Weisman), and Siebert Financial (co-CEOs), alongside a cluster of independent director appointments at Kraft Heinz, Flowers Foods, Universal Corp, and JLL. Financial results embedded in these filings reveal a mixed operating environment: Uber, Clover Health, and Xperi show strong growth, while PureCycle, MNTN, and PacBio face margin pressure or guidance cuts. Insider activity is limited, but executive departures at Children's Place, Electronic Servitor, and Astera Labs signal potential governance instability. Capital allocation remains shareholder-friendly, with Service Corp International declaring a dividend and Rallybio approving a special cash distribution. Forward-looking catalysts include the December PDUFA date for Mineralys, the Q1 2027 Cree LED sale by Penguin Solutions, and multiple CEO transitions effective in early 2027. Overall, the digest highlights a market in transition, with leadership changes often coinciding with strategic pivots or operational challenges.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from October 28, 2026.
Investment Signals (12)
- Clover Health ↓ (BULLISH)▲
Q3 revenue surged 52.9% YoY to $759.3M, GAAP net income swung to $6.4M profit from a $24.4M loss, and management raised full-year guidance; Insurance BER worsened 240 bps QoQ but improved 100 bps on a nine-month basis
- Uber Technologies ↓ (BULLISH)▲
Gross Bookings grew 20% YoY to $59.8B, Non-GAAP Operating Income up 38% YoY to $2.3B, and Non-GAAP EPS up 35% to $0.88; GAAP EPS fell 92% due to one-time items, but core operating momentum remains strong
- Xperi Inc. ↓ (BULLISH)▲
Q3 revenue grew 2.2% YoY to $114.0M, with Advertising revenue up 280% and Media Platform revenue doubling; raised adjusted EBITDA margin outlook to 19%-21% and operating cash flow to $20M-$30M
- Hecla Mining ↓ (MIXED)▲
Q3 revenue up 18% QoQ to $394.8M, record operating cash flow of $202.95M, and $692M cash with no drawn debt; however, silver AISC spiked to $14.34/oz from $6.07/oz, and Keno Hill milling rates will be suppressed
- Mineralys Therapeutics ↓ (BULLISH)▲
Lorundrostat reduced systolic BP by 11.1 mmHg in Explore-OSA, PDUFA date December 22, 2026, and cash of $624.7M funds operations into 2028; net loss widened to $57.3M as G&A rose to build launch capacity
- FrontView REIT ↓ (BULLISH)▲
Q3 AFFO rose to $9.7M ($0.33/share) from $8.8M, revenue grew 10.9% YoY, and FY2026 AFFO guidance maintained at $1.32-$1.34; net debt to EBITDA improved to 5.0x
- Sensient Technologies ↓ (NEUTRAL)▲
Board expanded to 10 with two new directors (Ernest Chan, Philip Yu) effective December 2, 2026, adding scientific and technology expertise; no financial data, but governance enhancement is positive
- Service Corp International ↓ (NEUTRAL)▲
Declared quarterly dividend of $0.36/share, payable December 31, 2026; consistent capital return with no performance red flags
- Penguin Solutions ↓ (MIXED)▲
Divesting Cree LED for cash to become pure-play AI infrastructure; reaffirmed fiscal 2027 outlook with Cree LED ~10% of sales, but transaction price undisclosed and guidance to be updated post-close
- PacBio (BEARISH)▲
Q3 revenue up 5.5% YoY to $40.6M, but gross margin compressed to 33% from 41% and cash declined to $199.4M; CFO transition adds uncertainty
- MNTN ↓ (BEARISH)▲
Q3 revenue growth decelerated to 15% from 21% in Q2, and Q4 guidance implies a significant step-down in Adjusted EBITDA to $8M-$10M from $19.9M; new CEO Tony Weisman faces execution challenges
- PureCycle Technologies ↓ (BEARISH)▲
Q3 revenue fell to $2.3M from $4.5M in Q2, liquidity dropped 18.5% to $193M, and ~50M pounds of expected annual volume pushed to 2027; net income positive only due to non-cash warrant gain
Risk Flags (10)
- PureCycle/Liquidity↓ [HIGH RISK]▼
Total liquidity declined $43.9M sequentially (18.5%) to $193M; Q4 project spend guided to ~$4M, but full-year spend raised to ~$51M above prior guidance
- MNTN/Growth Deceleration↓ [HIGH RISK]▼
Revenue growth slowed to 15% from 21% in Q2 and 25% in Q4 2025; management cited unforeseen go-to-market execution problems and cut full-year outlook
- PacBio/Margin Compression [HIGH RISK]▼
GAAP gross margin fell to 33% from 41% YoY, non-GAAP to 36% from 42%; cash declined to $199.4M from $298.7M; CFO resignation adds leadership instability
- Children's Place/Governance [HIGH RISK]▼
Cluster of resignations including President/Interim CEO, Chief Strategy Officer, and Executive Chairman within days; CFO becomes acting President by bylaw, raising governance concerns
- Hecla Mining/Cost Inflation↓ [MEDIUM RISK]▼
Silver AISC rose to $14.34/oz from $6.07/oz QoQ; Lucky Friday AISC at $27.68/oz; Keno Hill milling rates suppressed starting Q4, impacting future production
- Clover Health/Insurance Costs↓ [MEDIUM RISK]▼
Insurance BER deteriorated 240 bps QoQ to 91.1% in Q3, though nine-month improved; watch for continued pressure in Q4
- Electronic Servitor/Key Man Risk↓ [MEDIUM RISK]▼
One individual (Peter Hager) now holds CEO, COO, CFO, and Secretary roles for a 30-day term, concentrating executive functions and raising internal-controls concerns
- Rallybio/Shareholder Opposition↓ [MEDIUM RISK]▼
Equity incentive plan and ESPP passed with notable opposition (958K and 752K votes against), indicating shareholder concerns over dilution
- GRI Bio/Equity Plan↓ [MEDIUM RISK]▼
Equity plan amendment passed narrowly (136,205 for vs 102,978 against) with low quorum of 42.37%, signaling potential shareholder discontent
- Astera Labs/Director Departure↓ [LOW RISK]▼
Michael Hurlston resigned from board effective November 3, 2026; no reason given, but loss of a director may signal governance shifts
Opportunities (9)
- Mineralys Therapeutics/PDUFA Catalyst↓ (OPPORTUNITY)◆
Lorundrostat PDUFA date December 22, 2026; positive Phase 2 data (11.1 mmHg BP reduction) and cash runway into 2028; potential launch in a large hypertension market
- Uber Technologies/Operating Leverage↓ (OPPORTUNITY)◆
Non-GAAP Operating Income up 38% YoY, EPS up 35%; despite GAAP noise, core growth and margin expansion suggest continued upside
- Clover Health/Profitability Inflection↓ (OPPORTUNITY)◆
GAAP net income positive for Q3 and YTD; revenue growth 52.9% YoY with operating leverage (SG&A grew 26.5% vs revenue 52.9%); raised guidance
- Xperi/Advertising Growth↓ (OPPORTUNITY)◆
Advertising revenue up 280% YoY, TiVo One ARPU up 14% sequentially, MAUs up 40% YoY; raised margin and cash flow outlook
- FrontView REIT/Stable AFFO↓ (OPPORTUNITY)◆
AFFO per share up to $0.33 from $0.32, guidance maintained; accretive acquisitions at 7.56% cap rate with improving leverage
- Penguin Solutions/Divestiture Value↓ (OPPORTUNITY)◆
Sale of Cree LED to focus on AI infrastructure; potential for multiple expansion as pure-play AI company; watch for transaction price disclosure
- Hecla Mining/Record Cash Flow↓ (OPPORTUNITY)◆
Record operating cash flow and free cash flow; $692M cash with no debt; despite cost pressures, balance sheet strength supports long-term silver exposure
- HP Inc./New CEO Catalyst↓ (OPPORTUNITY)◆
Emma Walmsley (ex-GSK) appointed CEO effective January 4, 2027; her track record in transformation could drive strategic repositioning; watch for initial strategic announcements
- Processa Pharmaceuticals/Post-Merger Momentum↓ (OPPORTUNITY)◆
$200M private placement and new leadership team; VT-7208 IND cleared for Phase 2 in chronic spontaneous urticaria; potential for pipeline re-rating
Sector Themes (6)
- Board Refreshment with Financial Expertise◆
Multiple companies (Kraft Heinz, Flowers Foods, Universal Corp, InvenTrust, JLL) appointed directors with strong CFO or financial leadership backgrounds, indicating a trend toward adding financial oversight during transformation periods.
- CEO Transitions as Strategic Pivots◆
HP, MNTN, Siebert Financial, and Ensysce all announced CEO changes, often tied to strategic shifts (e.g., HP's new CEO, MNTN's turnaround, Siebert's co-CEO structure). Investors should monitor execution risks and strategic clarity.
- Mixed Earnings with Cost Pressures◆
Companies like Uber and Clover Health show strong top-line growth, but others (PacBio, PureCycle, MNTN) face margin compression or guidance cuts, highlighting a bifurcated market where operational efficiency is key.
- Shareholder Activism on Equity Plans◆
Rallybio and GRI Bio saw notable opposition to equity plan proposals, suggesting investors are increasingly scrutinizing dilution and compensation practices.
- Capital Allocation Focus◆
Service Corp International's dividend and Rallybio's special cash distribution indicate a continued focus on returning capital, while PureCycle's liquidity decline underscores the need for careful cash management in growth-stage companies.
- Governance Instability in Small Caps◆
Children's Place, Electronic Servitor, and Tevogen Bio experienced multiple executive/director departures, raising governance red flags and potential operational disruption.
Watch List (8)
-
FDA decision on lorundrostat due December 22, 2026; watch for label and launch preparation updates.
-
Cree LED sale to Transom Capital expected to close Q1 2027; watch for transaction price and updated fiscal 2027 guidance.
-
Emma Walmsley becomes CEO January 4, 2027; watch for strategic announcements and potential board changes.
-
Q4 guidance implies significant EBITDA step-down; watch for execution improvements and sales organization realignment updates.
-
Watch for Ironton operational improvements and progress on New Jersey food-contact exemption; liquidity levels critical.
-
Insurance BER worsened in Q3; watch for stabilization in Q4 and full-year guidance updates.
-
CEO transition and director resignation scheduled for December 14, 2026; watch for confirmation of leadership changes.
- Children's Place/Leadership Vacuum👁
Watch for permanent CEO appointment and any further board changes; governance stability is a key concern.
Filing Analyses
(34)
04-11-2026
Rallybio Corp held its Annual Meeting on November 4, 2026, where stockholders approved all proposals related to the pending merger with Avenzo Therapeutics, including the issuance of shares (representing >20% of outstanding stock and resulting in a change of control), a reverse stock split (1-for-2 to 1-for-9), a name change to 'Avenzo Therapeutics, Inc.', an increase in authorized shares from 200,000,000 to 500,000,000, the election of four Class II directors, ratification of Deloitte & Touche as auditor, and the adoption of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. The company also declared a special cash distribution of $83.6 million ($13.90 per share) to stockholders and pre-funded warrant holders of record as of November 5, 2026. While the merger-related proposals passed, Proposal 7 (2026 Equity Incentive Plan) and Proposal 8 (2026 ESPP) saw notable opposition, with 958,257 and 752,717 votes against, respectively.
- · Proposal 1 (issuance of shares) passed with 4,506,703 for, 15,979 against, 14 abstaining, and 267,624 broker non-votes.
- · Proposal 2 (reverse stock split) passed with 4,768,828 for, 21,477 against, 15 abstaining.
- · Proposal 3 (name change) passed with 4,770,644 for, 19,661 against, 15 abstaining.
- · Proposal 4 (increase authorized shares) passed with 4,275,569 for, 245,991 against, 1,136 abstaining, and 267,624 broker non-votes.
- · Proposal 5 (director elections) - all four nominees elected; Christine A. Nash had the lowest support with 4,431,749 for and 90,558 against.
- · Proposal 6 (ratify Deloitte & Touche) passed with 4,788,696 for, 1,612 against, 12 abstaining.
- · Proposal 7 (2026 Equity Incentive Plan) passed with 3,564,394 for, 958,257 against, 45 abstaining, and 267,624 broker non-votes.
- · Proposal 8 (2026 ESPP) passed with 3,760,074 for, 752,717 against, 9,905 abstaining, and 267,624 broker non-votes.
- · The Cash Distribution is payable to stockholders and pre-funded warrant holders of record as of November 5, 2026, subject to Nasdaq due bill procedures.
04-11-2026
Hecla Mining reported third quarter 2026 results with revenue from continuing operations of $394.8 million (up 18% QoQ, driven by timing of Greens Creek sales) and income from continuing operations of $149.6 million ($0.22/share, up from $117.9 million in Q2). Record cash provided by operating activities from continuing operations of $202.95 million and record free cash flow from continuing operations of $151.2 million were reported, with the company ending the quarter with $692 million in cash and no drawn debt. Mixed performance was evident: consolidated costs applicable to sales rose 35% QoQ to $158.2 million, silver AISC rose to $14.34/oz from $6.07/oz, Keno Hill milling rates will be suppressed starting Q4, and Lucky Friday AISC remained elevated at $27.68/oz, while year-to-date AISC of $9.37/oz was roughly flat versus $9.26/oz a year earlier.
- · Keno Hill milling rates will be suppressed beginning Q4 2026 to preserve tailings storage, waste rock and water treatment capacity pending license amendments
- · Lucky Friday silver AISC of $27.68/oz and cash cost of $7.31/oz deteriorated sharply versus prior quarter ($17.08/oz AISC)
- · Lucky Friday silver production fell 17% QoQ to 1.27M oz; Greens Creek production declined 5.6% QoQ to 1.94M oz
- · Greens Creek growth capex guidance revised; intermittent pyrite concentrate production may begin late 2027 subject to final investment approval, full capacity late 2028
- · Q4 2026 capital investment expected to increase as projects advance, including Keno Hill dry stack tailings expansion
- · Consolidated 2026 silver production guidance 15.3-16.1M oz (low end raised); AISC guidance improved to $11.50-$12.50/oz
- · Exploration progress: new mineralized extension at Keno Hill Flame & Moth; West Ore Offset massive sulfide intercepts at Greens Creek with assays pending
- · Board appointment of Dale Andres, mining executive with 35+ years experience in base and precious metals
04-11-2026
Uber reported Q3 2026 results with Gross Bookings up 20% YoY to $59.8 billion (20% constant currency) and Non-GAAP Operating Income up 38% YoY to $2.3 billion, with Non-GAAP EPS of $0.88 (up 35%). However, GAAP Diluted EPS fell 92% YoY to $0.25 because the prior-year quarter included a $4.9 billion tax valuation release and a $1.5 billion pre-tax equity revaluation gain, while Q3 2026 absorbed a $476 million pre-tax equity revaluation loss. Revenue grew only 10% YoY to $14.8 billion, held back by an 8-percentage-point drag from business model changes, and Mobility revenue declined 2%.
- · Mobility revenue declined 2% YoY to $7.5 billion while Mobility Gross Bookings grew 18%, reflecting business model changes that shifted revenue recognition
- · Corporate G&A and Platform R&D costs rose 13% YoY to $1.08 billion, widening the drag on segment profitability
- · Equity method investments rose to $3.5 billion from $287 million at year-end 2025, and long-term debt rose to $15.7 billion from $10.5 billion
- · Freight segment Non-GAAP operating loss narrowed to $(33) million from $(40) million YoY
- · Q4 2026 Non-GAAP EPS outlook of $0.95 to $0.99 implies 34% to 39% growth, and Adjusted EBITDA outlook of $3.13 to $3.23 billion
- · Officer change: CFO named as Balaji Krishnamurthy in the filing's Item 5.02 disclosure, per the preliminary event classification; the provided excerpt does not contain the Item 5.02 text itself, so the details of any transition should be verified against the full 8-K
04-11-2026
The Kraft Heinz Company (NYSE: KHC) announced that Kelly Dilts and J. Michael (Mike) Schlotman have been appointed to its Board of Directors, effective Nov. 4, 2026, as independent directors. Dilts is CFO of Nordstrom, Inc. and previously served as EVP and CFO at Dollar General Corporation; Schlotman spent more than 30 years at The Kroger Co., including almost 20 years as CFO. The appointments are presented as strengthening the Board during the company's transformation strategy.
- · Dilts oversees real estate and strategic sourcing at Nordstrom in addition to her CFO role
- · Dilts' Dollar General responsibilities included FP&A, procurement, margin planning, decision science and investor relations
- · Schlotman served on the Board of Kellanova prior to its acquisition by Mars, Incorporated in December 2025
- · Chairman Cahill cited the new directors' expertise in retail and customer channels as increasingly important
04-11-2026
Flowers Foods (NYSE: FLO) announced that its board elected Shaun P. Mara and Ken Plunk as independent directors effective November 18, 2026, increasing the board to 10 members; both were appointed to the audit and finance committees. The filing contains no financial results, guidance, or negative performance data, so the announcement is a governance update rather than a performance report.
- · Mara previously chaired the audit committee of Farmer Bros. Co. and retired as CFO of The Simply Good Foods Company in June 2025
- · Plunk currently serves on the boards of WD-40 Company and Milo's Tea Company, with audit, finance, risk, and governance committee responsibilities
- · Both new directors bring financial and transformation experience cited by the chairman as relevant to strengthening the portfolio and sharpening execution
04-11-2026
Fastly, Inc. announced that President, Go to Market Scott R. Lovett will retire on a date to be determined during 2027, under a transition and separation agreement dated October 30, 2026, during which he will support the hiring and onboarding of a new Chief Revenue Officer. He will then serve as a non-employee Senior Advisor through June 30, 2027, with his equity continuing to vest on existing schedules and a potential Change in Control acceleration provision.
- · Lovett will not be eligible for new equity awards during the transition period but existing awards continue to vest through the Consulting Period End Date
- · Single-trigger style acceleration: 100% of unvested equity vests on a Change in Control before the Retirement Date, with performance awards deemed achieved at the greater of target or actual
- · The separation agreement supersedes Lovett's offer letter and his participation in the Severance Plan
- · Company is searching for a new Chief Revenue Officer, indicating a planned leadership succession in revenue functions
- · Filing also furnishes a press release dated November 4, 2026 under Regulation FD (Exhibit 99.1)
04-11-2026
Tevogen Inc. (TVGN/TVGNW) disclosed that director Susan Podlogar resigned from the Board effective November 2, 2026. In connection with the resignation, the Board reduced its size from six to five directors and appointed current director Lindee Goh to the Audit Committee, effective the same date. The filing contains no financial results, so no period-over-period performance data is reported.
- · Board size reduced from six to five directors, effective November 2, 2026
- · Lindee Goh appointed to the Audit Committee, effective November 2, 2026
04-11-2026
Ensysce Biosciences disclosed that director Will Chang intends to resign following the Annual Meeting scheduled for December 14, 2026, and that CEO Dr. Lynn Kirkpatrick will relinquish the CEO title to become Chief Operating Officer immediately after that meeting, with President James Morrisson succeeding her as CEO. The filing also notes Dr. Kirkpatrick agreed to an amendment to her employment agreement confirming the COO role will not trigger severance, and discloses that she holds a 9.9% stake in EBIR, Inc., a subsidiary-related entity where she is also CEO. No financial results or quantitative performance metrics are reported.
- · Annual Meeting scheduled for December 14, 2026; CEO transition and Chang resignation are both tied to this date and will be delayed if the meeting is postponed
- · Mr. Chang has not yet provided a written resignation or a specific resignation date
- · Dr. Kirkpatrick's employment offer letter dated September 14, 2021 is being amended to confirm COO acceptance does not trigger severance
- · Dr. Kirkpatrick has served as CEO since January 2009
04-11-2026
PacBio reported Q3 2026 total revenue of $40.6 million, up from $38.4 million in Q3 2025 (+5.5%), with Revio placements rising to 15 from 13 and Vega placements to 35 from 32. However, GAAP gross margin compressed to 33% from 41%, non-GAAP gross margin fell to 36% from 42%, and ending cash, cash equivalents and investments declined to $199.4 million from $298.7 million. Net loss was roughly flat year over year at $37.8 million GAAP versus $38.0 million, and the company lowered its outlook is not stated; it set full-year 2026 revenue guidance of $155 million to $160 million. The CFO, Jim Gibson, stepped down, with Mark Van Oene named interim CFO and Bill Meyer appointed Chief Accounting Officer while a search for a permanent CFO begins.
- · Consumable revenue declined 2.3% YoY to $20.8M, despite SPRQ-Nx adoption; over half of Revio consumables revenue is now tied to SPRQ-Nx
- · Annualized Revio pull-through per system fell about 14% YoY to roughly $204K from $236K
- · Non-GAAP gross margin decline was attributed to higher memory costs and Vega manufacturing transition costs
- · Nine-month GAAP net loss narrowed to $90.9M from $506.0M, but the prior-year period included a $363.7M amortization charge and $15.0M impairment
- · Nine-month 2026 operating results include a $15.4M litigation settlement with Personal Genomics of Taiwan, Inc. and a $45.8M gain on disposal of assets
- · Cash balance down about $99M YoY, reflecting ongoing cash burn against a net loss of roughly $38M per quarter
04-11-2026
Thunder Mountain Gold Inc. (OTCQB: THMG; TSX-V: THM) announced the appointment of Ron Clayton to its Board of Directors, effective October 1, 2026, with the news release dated October 5, 2026 and the 8-K filed November 4, 2026. Mr. Clayton brings more than 40 years of mining industry experience and currently chairs i-80 Gold Corporation. The filing contains no quantitative financial results, amounts, or period-over-period comparisons.
- · Ron Clayton holds a B.S. in Mining Engineering from the Colorado School of Mines and completed the Tuck Executive Education Program at Dartmouth
- · Ron Clayton chairs the Technical, Safety, Environmental and Sustainability Committee at i-80 Gold Corporation
- · Ron Clayton previously served as President, CEO and director of Tahoe Resources Inc. and 1911 Gold Corporation
04-11-2026
Mineralys Therapeutics reported Q3 2026 results with a net loss of $57.3 million, up from $36.9 million a year earlier, as G&A rose sharply to $37.4 million (from $9.7 million) to build commercial launch capacity, while R&D fell to $22.7 million (from $31.5 million) after the pivotal program concluded in Q2 2025. Cash, cash equivalents and investments were $624.7 million, versus $656.6 million at December 31, 2025, and management says this is sufficient to fund operations, including the lorundrostat launch, into 2028. The company remains on track for the December 22, 2026 PDUFA target date for lorundrostat, with new Launch-HTN and Explore-OSA data presented and a Transform-HTN late-breaker scheduled at AHA 2026. Performance is mixed: the pipeline and regulatory news is positive, but operating losses widened and interest expense began following the June 2026 senior secured term loan.
- · Lorundrostat reduced morning systolic blood pressure by 11.1 mmHg at Week 4 in Explore-OSA vs a 1.0 mmHg reduction with placebo, with no measurable change in apnea-hypopnea index
- · Launch-HTN CKD analysis showed similar blood pressure reductions in participants with and without CKD across Stages 1-3
- · Interest expense of $3.2M in Q3 2026 related to the senior secured term loan entered into in June 2026, partially offset by higher interest income
- · Nine-month 2026 R&D expense rose to $268.4M from $107.6M in the prior-year period, a substantial increase in the year-to-date period
- · Nine-month 2026 G&A expense rose to $83.1M from $24.7M; total nine-month 2026 operating loss was $351.5M
- · Q3 G&A increase reflected $15.4M in higher professional fees and $11.4M in higher personnel-related expenses
- · Q3 R&D decrease reflected $8.5M lower preclinical and clinical costs following conclusion of the pivotal program in Q2 2025
- · Total liabilities rose to $126.3M from $15.1M, driven by the term loan
04-11-2026
Cornerstone Building Brands, Inc. disclosed in an 8-K dated October 29, 2026 that its Compensation Committee approved changes to the compensation of Matt Ackley, whose title changed from President, Metal Solutions to Chief Executive Officer, Fortify Building Solutions in connection with the renaming of the business unit he leads. His base salary was raised from $520,000 to $750,000 (a 44.2% increase), and his target annual incentive rose from 75% to 100% of base salary.
- · The Compensation Committee of the Board approved the changes on October 29, 2026
- · The filing was signed November 4, 2026, with the event date of October 29, 2026
04-11-2026
Clover Health reported Q3 2026 results with GAAP net income of $6.4M (vs. a $24.4M loss a year earlier) and total revenues of $759.3M, up 52.9% YoY, alongside Medicare Advantage membership of 158,907, up 45% YoY. Year-to-date GAAP net income reached $61.8M, and management raised full-year 2026 guidance across most metrics. Performance was mixed: Insurance BER deteriorated to 91.1% from 93.5% (240 bps worse), and nine-month Adjusted SG&A as a percentage of revenue improved only modestly to 15.3% from 16.5%, while the Q3 ratio rose 70 bps to 15.0%.
- · Insurance BER worsened 240 bps in Q3 to 91.1%, though nine-month BER improved 100 bps to 88.4%
- · Q3 Adjusted SG&A as % of revenue rose 70 bps to 15.0%, while the nine-month ratio fell 120 bps
- · Q3 SG&A grew 26.5% YoY versus 52.9% revenue growth, indicating operating leverage
- · Full-year GAAP net income guidance of $25M-$35M is only modestly above the $61.8M already earned through nine months, implying a Q4 loss
- · Company discontinued Normalized Insurance Benefits Expense Ratio disclosure beginning Q1 2026
- · Officer Change flagged in preliminary classification; press release itself does not describe an officer departure, only CEO and CFO quotes
04-11-2026
MNTN reported Q3 2026 revenue of $80.3 million, up 15% year-over-year, with net income of $7.7 million (up 19%) and Adjusted EBITDA of $19.9 million (up 24%). However, growth decelerated sharply from 21% in Q2 2026 and 25% in Q4 2025, the company cited unforeseen go-to-market execution problems, and it cut full-year 2026 revenue and Adjusted EBITDA outlook. The company also named Tony Weisman, a board member and former CMO of Dunkin' U.S. and CEO of Digitas, as President and CEO, succeeding Mark Douglas.
- · Q3 2026 revenue growth decelerated to 15% from 21% in Q2 2026 and 25% in Q4 2025, a notable slowdown
- · Management attributed the Q3 revenue shortfall to unforeseen execution problems in the go-to-market organization and is realigning the sales organization
- · Q4 2026 revenue guidance of $75M-$78M and Adjusted EBITDA guidance of $8M-$10M, implying a significant step-down from Q3 Adjusted EBITDA of $19.9M
- · Full-year 2026 guidance was updated downward, with 10% midpoint growth excluding the Maximum Effort divestiture versus 8% on a GAAP basis
- · Q3 2026 gross margin of 79% was down from 80% in Q2 2026 and 81% in Q1 2026
- · Company has $252.3M in cash with no borrowings outstanding
- · Board appointment of Mike Katz (former T-Mobile President) and executive appointments of a new CMO, SVP of Agency Partnerships, and SVP of Inside Sales
- · Earnings call scheduled for November 4, 2026 at 4:30 p.m. ET
04-11-2026
PureCycle reported Q3 2026 revenue of $2.3 million, down from $4.5 million in Q2 2026 and flat versus $2.4 million in Q3 2025, reflecting Ironton operational issues and the New Jersey food-contact exemption extension that pushed about 15 programs (roughly 50 million pounds of expected annual volume) into 2027. Net income of $6.9 million was driven by a $58.6 million non-cash warrant fair-value gain, while Adjusted EBITDA of $(28.0) million was only $0.6 million better year over year and total liquidity fell to $193 million from $236.9 million in Q2. Positives include P&G products on shelves, railcar shipments starting in October, monthly operations spending below guidance, and the appointment of Fernando Musa as Executive Chairman effective November 3, 2026.
- · Net income was positive only because of the $58.6M non-cash warrant fair-value gain; the underlying operating loss was $37.5M
- · Total liquidity declined $43.9M sequentially, roughly 18.5%, from Q2 to Q3 2026
- · Q4 2026 project spend guided to ~$4M, with full-year 2026 project spend raised to ~$51M, above the $45-50M range given in August
- · Project and growth spending is expected to be directionally lower in 2027, with a 2027 range to be provided with Q4 results
- · Chairman Dan Coombs stepped down; Fernando Musa, a Board member since 2021, became Executive Chairman, while Dustin Olson remains CEO
- · Capital structure unchanged from June 2026 refinancing except the August 2026 revolver maturity extension to September 30, 2028
- · Potential future capital sources of ~$76M revenue bonds, ~$67.3M original-cost equipment financing and ~$272M warrant proceeds are not assumed in liquidity planning
- · Growth projects have reached internal milestones and discretionary spending is on hold until Ironton commercial progress supports further investment
04-11-2026
FrontView REIT reported Q3 2026 results with net income of $3.0M ($0.08/share), down from $5.5M ($0.19/share) a year earlier, while FFO ($7.4M, $0.25/share) was flat year over year and AFFO rose to $9.7M ($0.33/share) from $8.8M ($0.32/share). Revenue grew 10.9% YoY to $18.6M, and the company acquired 16 properties for $50.6M at a 7.56% cap rate while disposing of 5 properties for $17.1M. The board also promoted CFO Pierre Revol to President, and FY2026 AFFO guidance of $1.32-$1.34 per share was maintained.
- · Net Debt to Annualized Adjusted EBITDAre improved to 5.0x; Adjusted Net Debt to Annualized Adjusted EBITDAre was 4.5x; Fixed Charge Coverage Ratio was 3.5x
- · Investment-grade tenant share was 28.5% of Q3 acquisitions and 33.5% of the total portfolio
- · Q3 2026 weighted average lease term on acquisitions was 6.4 years vs 7.5 years for nine-month acquisitions; disposition WALT was 6.4 years vs 8.3 years YTD
- · Only 9,373 shares were sold under the ATM at $21.01 (about $0.2M) in Q3, with 1.7M forward shares settled for $32.7M
- · Cash fell to $5.0M from $13.5M at year-end 2025, while debt, net declined to $310.3M from $314.3M
- · Accumulated deficit widened to $(40.7)M from $(28.1)M at December 31, 2025
- · Management expects acquisition yields to move higher in Q4 2026 and expects to meet or exceed full-year net investment guidance, while the guidance range of ~$120.0M in net investment was maintained
- · Quarterly dividend of $0.215 per share (AFFO payout ratio 64.7%) declared for payment January 15, 2027, to holders of record December 31, 2026
- · Giant Eagle, a 2026 investment-grade tenant, is subject to an agreement to be acquired by Kroger
- · Conference call scheduled for November 5, 2026 at 10:00 a.m. Central Time
04-11-2026
Sensient Technologies (SXT) increased its Board from nine to ten members on October 29, 2026 and elected Ernest Chan and Philip Yu as directors, effective December 2, 2026. One seat fills the vacancy left by the September 2026 passing of director Essie Whitelaw; the other is newly created. Both will serve on the Scientific Advisory Committee and receive standard non-employee director compensation, including a pro-rated 2026 cash retainer.
- · Messrs. Chan and Yu serve until the 2027 annual shareholder meeting or until successors are elected and qualified.
- · No arrangements or understandings exist between either nominee and any other person for their selection, and neither has a related-party transaction requiring Item 404(a) disclosure.
- · Chan's RF Technologies focuses on safety technology (real-time location, staff protection, wander management, emergency call) for healthcare and senior living; Yu's IMSAR LLC develops low-SWaP synthetic aperture radar payloads for unmanned and manned aircraft.
04-11-2026
InvenTrust Properties Corp. (NYSE: IVT) announced the appointment of Robert A. Garechana to its Board of Directors, effective immediately, as an independent director and member of the Audit Committee. Garechana currently serves as EVP and CFO of Sun Communities, Inc., and previously held senior roles at Equity Residential, including CFO from 2018 to 2025. The filing contains no quantitative financial results, so there is no period-over-period performance data to balance.
- · Garechana previously served as Executive Vice President and Chief Investment Officer of Equity Residential in 2025 and as Treasurer from 2008 to 2018
- · Garechana also served as Treasurer and Vice Chairman of the Board of Upwardly Global, a nonprofit supporting work-authorized immigrants and refugees
- · Garechana holds a B.B.A. from the University of Texas at Austin
04-11-2026
Universal Corporation (NYSE: UVV) announced the appointment of Gregory R. Friedman to its Board of Directors, effective November 4, 2026. Friedman brings more than 30 years of financial, operational, and strategic leadership, most recently as CFO of Mura Technology and previously as EVP and CFO of Corteva, Inc. The filing is a board-level governance addition and contains no reported financial results, so no period-over-period performance comparison is presented.
- · Friedman previously served on the Audit and Compensation and Human Resources Committees of Radius Recycling (NASDAQ: RDUS), adding public company governance experience
- · Friedman helped Corteva through its separation from DowDuPont and its establishment as an independent public company, and shaped its capital structure and financial policy
- · Friedman held senior finance roles at DuPont, including VP of Investor Relations and CFO of DuPont Pioneer
04-11-2026
HP Inc. announced that its Board unanimously appointed Emma Walmsley, former CEO of GSK, as Chief Executive Officer effective January 4, 2027, succeeding Interim CEO Bruce Broussard, who will become Chair of the Board on the same date, succeeding Chip Bergh. The filing reports leadership continuity and a planned executive transition but contains no financial results, guidance, or quantitative performance data.
- · Walmsley served as GSK CEO from April 2017 through December 2025 and led a transformation focused on specialty medicines and vaccines and separation of the consumer healthcare business
- · Walmsley has been a Microsoft board member for seven years
- · Broussard has served as Interim CEO since February 2026
- · Bergh has been HP Board Chair since 2017 and a director since 2015
- · The search process was described as comprehensive and global
04-11-2026
Xperi Inc. reported Q3 2026 revenue of $114.0M, up 2.2% YoY from $111.6M, driven by a 280% surge in Advertising and Related revenue which helped Media Platform revenue double year-over-year. However, GAAP net loss improved to -$5.2M from -$6.1M, while Non-GAAP net income declined to $11.7M from $12.8M and Non-GAAP adjusted EBITDA margin slipped to 20.2% from 20.7%. The company narrowed its 2026 revenue outlook to $450M-$462M and raised its adjusted EBITDA margin outlook to 19%-21% and operating cash flow to $20M-$30M. CFO Robert Andersen will retire in 2027 as part of a planned transition.
- · TiVo One ARPU of $7.65 increased 14% sequentially from last quarter.
- · TiVo One Monthly Active Users grew 40% YoY to 6.8 million.
- · DTS AutoStage has shipped more than 18 million cars across 13 automotive brands in over 150 countries.
- · Global IPTV subscriber households stood at 3.42 million at the end of Q3.
- · The company raised its 2026 adjusted EBITDA margin outlook to 19%-21% (from 17%-19%) and operating cash flow outlook to $20M-$30M (from $15M-$25M).
- · Capital expenditures for 2026 are expected to be approximately $25M.
- · Non-GAAP tax expense for 2026 is expected to be approximately $20M.
- · Stock-based compensation for 2026 is expected to be approximately $29M.
04-11-2026
Noble Corporation plc promoted Joey M. Kawaja from Senior Vice President of Operations to Executive Vice President and Chief Operating Officer, effective November 1, 2026. The filing is a routine 8-K disclosure of an officer change and contains no financial data or performance metrics.
- · Joey M. Kawaja had been Senior Vice President of Operations since October 2022 before the promotion.
- · The promotion is effective November 1, 2026.
- · The filing was signed by Jennie Howard, Senior Vice President, General Counsel and Corporate Secretary.
04-11-2026
Atmos Energy Corporation announced the retirement of Chairman Kim R. Cocklin effective at the 2027 annual meeting, with CEO J. Kevin Akers assuming the Chairman role. The Board approved combining the Chairman and CEO roles, and Lead Director Nancy K. Quinn will continue in her position. The transition is orderly and planned, with no negative financial impact indicated.
- · Kim R. Cocklin has served on the Board since 2006 and as Chairman since December 2020.
- · Cocklin reached mandatory retirement age under the Company's Corporate Governance Guidelines.
- · The Board approved combining the roles of Chairman and CEO effective upon Cocklin's retirement.
- · J. Kevin Akers' appointment as Chairman is subject to his re-election as a director at the 2027 Annual Meeting.
- · Nancy K. Quinn will continue as Lead Director, subject to her re-election.
- · Atmos Energy serves approximately 3.4 million distribution customers across eight states.
04-11-2026
Michael Hurlston resigned from the Board of Directors of Astera Labs, Inc., effective November 3, 2026. The resignation was not due to any disagreements or issues related to the company's operations, policies, or practices.
- · Resignation effective November 3, 2026.
- · No disagreements between Mr. Hurlston and the company.
- · Resignation not related to company operations, policies, or practices.
04-11-2026
GRI Bio, Inc. held its 2026 Annual Meeting on November 4, 2026, where stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing shares reserved by 546,529 and extending the evergreen provision to 2036. Directors W. Marc Hertz and David Szekeres were elected as Class III directors. However, the equity plan proposal passed with only 136,205 votes for versus 102,978 against, indicating significant shareholder opposition, and the meeting had a low quorum of 42.37%.
- · The equity plan amendment passed with a relatively narrow margin: 136,205 for vs. 102,978 against (excluding 684,435 broker non-votes).
- · Ratification of WithumSmith+Brown, PC passed overwhelmingly with 883,489 votes for.
- · The adjournment proposal passed with 828,697 votes for.
- · Broker non-votes were 684,435 on director elections and the equity plan proposal, indicating significant shares not voted by brokers.
04-11-2026
Electronic Servitor Publication Network, Inc. (NASDAQ/OTC symbol XESP) disclosed that Thomas Spruce resigned effective October 29, 2026 as Director, Chief Operations Officer, Chief Financial Officer, and Secretary, stating the resignation was not due to any disagreement with the Company. Effective November 3, 2026, President and CEO Peter Hager was appointed interim Director, COO, CFO, and Secretary for a 30-day term unless extended by mutual written agreement ratified by majority shareholders. The filing contains no financial results, so no period-over-period performance data is reported.
- · Peter Hager, age 57, has about 30 years of cross-industry executive experience and has led Pointward, Inc., a MedTech customer engagement agency, since 2003.
- · The Company is Delaware-incorporated, headquartered in Stillwater, MN, and was formerly known as CannAssist International Corp and Iris Grove Acquisition Corp.
- · The interim appointment means one individual now holds CEO, COO, CFO, and Secretary roles, a concentration of executive functions that investors may weigh against governance and internal-controls considerations.
- · The filing states Spruce's resignation was not due to any disagreement, and includes his resignation letter as Exhibit 17.1.
04-11-2026
Processa Pharmaceuticals announced the appointment of four senior leaders: Gregory J. Flesher as Chief Operating Officer, and Craig Coburn, Ph.D., Ashley Hall, J.D., and Michael P. Cruse as Executive Vice Presidents. The appointments follow the July 2026 acquisition of Vidya Therapeutics via a sign-and-close reverse merger and a concurrent private placement of approximately $200 million, and support the lead program VT-7208, a Bruton's tyrosine kinase inhibitor being developed across food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis. The filing contains no quantitative performance results, so no period-over-period comparison is available.
- · Craig Coburn was one of the scientists who helped invent VT-7208 and has served as a scientific advisor to Vidya Therapeutics since 2024
- · FDA cleared the IND application for the planned Phase 2 study of VT-7208 in chronic spontaneous urticaria
- · Ashley Hall previously worked on regulatory programs for NEXLETOL, NEXLIZET, and REPATHA at Esperion Therapeutics and Amgen
- · Gregory Flesher previously served as CEO of Ambros Therapeutics, Reneo Pharmaceuticals, and Novus Therapeutics
- · Michael Cruse most recently served as COO of Ambros Therapeutics, following prior COO role at Reneo Pharmaceuticals
- · The filing includes forward-looking statement risks, including ability to integrate Vidya, retain new executives, advance VT-7208 through clinical development, and need for additional capital
04-11-2026
JLL announced that Nabeel Al-Amudi and Toni Townes-Whitley were elected as independent, non-executive directors effective December 1, 2026, expanding the Board to 13 members. Al-Amudi, a former JLL CEO, now serves as senior advisor and vice chairman of Olayan Financing Company, while Townes-Whitley most recently served as CEO of SAIC. The appointments are presented as adding global investment, infrastructure, technology and regulated-industry experience to support the Accelerate 2030 strategy.
- · Both new directors are independent, non-executive members of the Board
- · Al-Amudi previously served as Saudi Arabia's minister of transport and holds a Juris Doctor from Harvard Law School
- · Townes-Whitley previously held roles at Microsoft (President of U.S. Regulated Industries), CGI, Unisys and Arthur Andersen and currently sits on the Nasdaq Inc. board
- · Al-Amudi's transition from JLL CEO to his current Olayan role is described as a move after serving as CEO; his board service at JLL is a new role
04-11-2026
The Children's Place disclosed a cluster of leadership changes: director Kim Roy resigned from the board effective October 30, 2026; President and Interim CEO Muhammad Asif Seemab and Chief Strategy Officer Muhammad Umair resigned effective November 1, 2026, with both remaining on the board; and Executive Chairman Turki Saleh A. AlRajhi resigned that role effective November 3, 2026, while staying on as Chairman of the Board. CFO John Szczepanski becomes acting President and principal executive officer by bylaw operation. All resignations were stated to be unrelated to any disagreement with the company.
- · Seemab and Umair remain on the board after their executive resignations, so the board composition is unchanged by those two exits.
- · Szczepanski took the acting President and principal executive officer role under Article III, Section 5 of the bylaws, with no new or modified compensatory arrangements tied to the change.
- · AlRajhi retains the Chairman title and two committee chair positions despite leaving the Executive Chairman role.
- · The filing references the April 10, 2026 proxy statement for Szczepanski's background and compensation details, and states no family relationships or Item 404(a) transactions beyond those disclosed there.
- · The filing does not name a permanent CEO or announce a search, leaving executive leadership in an interim state.
04-11-2026
Siebert Financial Corp. (SIEB) disclosed on an 8-K filed November 4, 2026 that its Board appointed Richard S. Gebbia and David J. Gebbia as Co-Chief Executive Officers effective November 4, 2026. John J. Gebbia, the current CEO, steps away from the CEO role on that date and will continue as Chairman of the Board. The filing discloses no financial results, amounts, or percentage changes.
- · Richard S. Gebbia previously served as CEO and a board member of StockCross Financial Services, Inc. from 2007 to 2020, until StockCross merged into Muriel Siebert & Co., LLC, a wholly owned Company subsidiary.
- · David J. Gebbia currently serves as President of the Company's insurance subsidiary Park Wilshire Companies, Inc. and of its entertainment and sports subsidiary Gebbia Holdings, LLC.
- · Both appointees are sons of John J. Gebbia; the filing states no arrangements or understandings exist with any other person regarding their selection as executive officers.
04-11-2026
Penguin Solutions (Nasdaq: PENG) has entered into a definitive agreement to sell its Cree LED business to Transom Capital Group in an all-cash transaction, expected to close in Q1 calendar 2027, as it becomes a pure-play data center AI infrastructure company. The company reaffirmed its fiscal 2027 outlook, which includes Cree LED at roughly 10% of projected fiscal 2027 net sales, and said it will update guidance after closing. Management cited 58% year-over-year net sales growth in the second half of fiscal 2026, though the release does not disclose the transaction price or any post-divestiture figures.
- · Transaction is all-cash and expected to close in Q1 calendar 2027, subject to customary closing conditions
- · Penguin plans to update fiscal 2027 outlook after closing to reflect the divestiture
- · Forward-looking statements flag risks including the transaction not closing, separation disruption, and benefits taking longer to realize
- · Cree LED is described as having more than 35 years of innovation and serving lighting, displays, horticulture and specialty applications
04-11-2026
Creatd, Inc. (OTCQB: CRTD) appointed Claudia Albelais, previously its Controller, as Chief Financial Officer and named Chelsea Pullano, a former Creatd CFO, as an independent director and chair of the Governance Committee, bringing the Board to five members. The Company frames the changes as strengthening its finance, reporting and governance structure as it works toward a national exchange listing. The release contains no quantitative financial results.
- · Pullano previously served as Creatd's Chief Financial Officer during an earlier stage of the Company's development
- · Albelais joined Creatd as Controller earlier in 2026 and oversees accounting, audit coordination and financial reporting
- · Albelais' CFO remit includes capital-structure work
04-11-2026
Service Corporation International (NYSE: SCI) announced that its Board of Directors approved a quarterly cash dividend of $0.36 per share of common stock, payable December 31, 2026 to shareholders of record as of December 15, 2026. The filing reflects a routine capital return action with no performance metrics disclosed, and the company reiterates that future dividends remain subject to Board determination each quarter.
- · Dividend record date is December 15, 2026 and payment date is December 31, 2026
- · Company operates in 44 states, eight Canadian provinces, the District of Columbia, and Puerto Rico
- · Company references its 2025 Annual Report on Form 10-K for risk factors
04-11-2026
Thunder Mountain Gold announced the appointment of Dr. Steven Osterberg as Senior Vice President of Exploration, effective immediately, and that Ron Espell has stepped down as Chief Operating Officer. The company also highlighted its South Mountain polymetallic project, which now totals approximately 13,061 acres following recent land acquisitions, and reported roughly US$25 million invested in the project since 2007.
- · Dr. Osterberg is a Qualified Person (P.G., Q.P.) who also reviewed and approved the technical data in the release
- · Espell contributed operational, environmental, and permitting expertise during his tenure as COO
- · Trout Creek Project in Nevada is a 100%-owned gold exploration asset adjacent to Nevada Gold Mines
- · South Mountain mineralization includes zinc, silver, gold, copper, and lead, with targets for silver-zinc massive sulfide and copper-gold
Get daily alerts with 12 investment signals, 10 risk alerts, 9 opportunities and full AI analysis of all 34 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Corporate Board Director Changes SEC Filings
October 27, 2026
US Corporate Board Director Changes SEC Filings — October 27, 2026
October 26, 2026
US Corporate Board Director Changes SEC Filings — October 26, 2026
October 23, 2026
US Corporate Board Director Changes SEC Filings — October 23, 2026
October 22, 2026
US Corporate Board Director Changes SEC Filings — October 22, 2026
🇺🇸 More from United States
View all →October 28, 2026
US Pre-Market SEC Filings Roundup — October 28, 2026
US Pre-Market SEC Filings Roundup
October 28, 2026
S&P 500 Financials Sector SEC Filings — October 28, 2026
S&P 500 Financials Sector SEC Filings
October 28, 2026
US Activist Hedge Fund Institutional SEC 13D 13G — October 28, 2026
US Activist Hedge Fund Institutional SEC 13D 13G
October 28, 2026
Nasdaq 100 Stocks SEC Filings — October 28, 2026
Nasdaq 100 Stocks SEC Filings